What a PD-L1 score means

A PD-L1 score is not a grade for your cancer. It is a measurement of one protein on the surface of your tumour cells, and it exists to help answer a single question: is a particular immunotherapy medicine likely to help you?

MedlinePlus puts the test itself simply. A PD-L1 test uses a sample of cancerous tumour tissue to measure how much of a protein called programmed-death ligand 1 is found on the cancer cells.

That is the whole test. A piece of tumour, and a measure of how much of one protein sits on it.

PD-L1 acts as a brake on the immune system. In healthy tissue that brake is useful, because it stops immune cells attacking normal parts of your body.

Some cancers use the same brake. By displaying PD-L1, they keep the immune system from attacking them. The cancer is, in effect, holding up a sign that says leave me alone.

Immunotherapy medicines are built to release that brake. So it helps to know how hard the brake is being pressed before you start.

The score describes the cancer's defence, not how fast it is growing.

This is a tissue test, not a blood test. That surprises people who expect a simple blood draw.

MedlinePlus describes the sample coming from tumour tissue removed during surgery, or from a biopsy. Biopsy methods include fine needle aspiration, core needle biopsy, surgical biopsy and endoscopic biopsy.

If you have already had surgery or a biopsy, there may be stored tissue the laboratory can use. That is worth asking about, because it can save you a second procedure.

MedlinePlus notes that side effects from a biopsy, such as bruising, soreness or infection, are usually mild and temporary.

The test is not run on everyone. MedlinePlus lists cancers where people with high PD-L1 levels may benefit from immunotherapy: non-small cell lung cancer, melanoma, Hodgkin lymphoma, bladder cancer, kidney cancer, breast cancer, head and neck cancer, oesophageal cancer, stomach cancer and cervical cancer.

Pembrolizumab, nivolumab and atezolizumab are named as common examples of immunotherapy medicines.

MedlinePlus describes what the result tells you. Your test results will show whether you have enough PD-L1 protein in your tumour for you to benefit from a specific immunotherapy medicine.

A high level suggests immunotherapy may help. A low level suggests it likely will not, and that other approaches are needed.

The result can also shape how a medicine is used. MedlinePlus describes it helping a provider choose between immunotherapy on its own and immunotherapy combined with chemotherapy.

This is the part worth holding on to. May benefit is not the same as will benefit.

MedlinePlus is direct that immunotherapy can cause serious side effects, and that not everyone benefits from it. A high score opens a door. It does not tell you what is behind it.

A low score is not a dead end either. It means this particular route is unlikely to be the right one, and your team will be looking at others.

Because scoring methods differ and results are read alongside everything else, the useful questions are specific ones.

• What was my result, and how was it scored?
• Was it run on recent tissue, or an older sample?
• Does it change what you are recommending, or confirm it?
• If immunotherapy is an option, what side effects should I watch for?

You do not need to understand the laboratory method to ask those. You only need to know that the number is one input into a decision, and that the decision is still yours to be part of.